thymalfasin (zadaxin) Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(C)=O)C(C)C)[C@@H](C)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)O)C(C)C)C(C)C)[C@@H](C)O)[C@@H](C)O
  • InChIKey: NZVYCXVTEHPMHE-ZSUJOUNUSA-N
  • Mol. Mass: 3108.31
  • ALogP: Missing data
  • ChEMBL Molecule:
    thymalfasin  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

alpha1-thymosin | emz702 | thymalfasin | thymosin alpha | thymosin alpha1 | thymosin alpha 1 | thymosin alpha(1) | zadaxin

Organizations (45)

Research & Development (45)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (26)

Approved Indications (1)


 

Neoplasms

Experimental Indications - Clinical Trial Phases 1-4 (26)


 

Adenocarcinoma of Lung (Phase 2)

Carcinoma, Hepatocellular (Phase 4)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Colorectal Neoplasms (Phase 2)

COVID-19 (Phase 3)

Esophageal Neoplasms (Phase 2)

Hematologic Neoplasms (Phase 1/Phase 2)

Hepatitis B ()

Hepatitis B, Chronic (Phase 4)

Hepatitis C (Phase 3)

Hepatitis C, Chronic (Phase 3)

Hepatitis, Viral, Human (Phase 1)

HIV Infections (Phase 3)

Kidney Failure, Chronic (Phase 2)

Liver Cirrhosis (Phase 4)

Lung Neoplasms (Phase 2)

Melanoma (Phase 2)

Neoplasms (Phase 3)

Pancreatitis, Acute Necrotizing (Early Phase 1)

Quality of Life (Phase 3)

Radiation Oncology (Phase 2)

Radiotherapy (Phase 2)

Respiratory Distress Syndrome (Phase 4)

Sepsis (Phase 4)

Small Cell Lung Carcinoma (Phase 2)

Thymalfasin (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 36
  • # of Trial Organizations: 45

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue